St. Jude Medical to Showcase New Lesion Assessment Technology at TCT 2010

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, will highlight recently launched technology, including its new Optical Coherence Tomography (OCT) product platform, at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. The new C7-XR™ OCT Intravascular Imaging System complements the company’s PressureWire™ Fractional Flow Reserve (FFR) measurement technology platform, offering physicians a new diagnostic standard for comprehensive intravascular lesion assessment.

The C7-XR OCT Intravascular Imaging System is a leading imaging technology platform that aids physicians in the diagnosis and treatment of cardiovascular disease. The C7-XR System uses near-infrared light to create high-resolution images that allow physicians to visualize and measure important vessel characteristics otherwise invisible or difficult to assess with older imaging technology. The St. Jude Medical OCT product platform expands the company's lesion assessment portfolio, which includes the recently launched PressureWire™ Aeris FFR Measurement System, and adds anatomical knowledge to the physiological information provided by FFR measurements. While FFR accurately identifies which lesions to stent, OCT-guided treatment can be especially important for the assessment of stent placement because it shows precisely how the stent is positioned against the artery wall.

“St. Jude Medical is pleased to introduce the first OCT system cleared for U.S. distribution at TCT 2010,” said Frank J. Callaghan, president of the St. Jude Medical Cardiovascular Division. “Combined with our leading FFR platform, these technologies assist physicians by optimizing their patients’ coronary interventions through comprehensive disease assessment, employing both anatomic and physiologic evidence. We are proud that St. Jude Medical is the first to offer both OCT and FFR technologies and we look forward to an integrated system in the future.”

In addition to guiding stent selection, the C7-XR System provides physicians with post-stenting information by evaluating the position and deployment of the stent. At follow-up, the OCT technology provides detailed information regarding the inner lining of the vessel and whether there is a reoccurrence of the blood vessel narrowing.

The company’s C7-XR OCT Intravascular Imaging System and PressureWire FFR measurement technology system will be demonstrated at TCT and will be on display at the St. Jude Medical booth (#1432). The St. Jude Medical Angio-Seal™ Evolution™ vascular closure device will also be featured.

OCT/FFR Virtual Reality Simulation Sessions

Physicians can learn more about OCT-guided therapy by participating in St. Jude Medical virtual reality simulations, debuting for the first time at TCT. The simulator enables physicians to manipulate the C7-XR Dragonfly™ Catheter, performing OCT-guided procedures in human-size models and selecting from a variety of case scenarios. The virtual reality sessions will take place on Sept. 23 and Sept. 24 from 9 a.m. to 5 p.m. and on Sept. 25 from 9 a.m. to 2 p.m. at the St. Jude Medical booth (#1432).

Physicians can also learn more about physiological lesion assessment by simulating the St. Jude Medical PressureWire FFR measurement technology. The FFR virtual reality sessions will take place at the St. Jude Medical booth (#1432).

Scientific Symposium

With recent clinical data and technology improvements, the incorporation of FFR and OCT into daily practice is growing at a rapid pace. To expand on the future potential of these technologies, St. Jude Medical will sponsor a scientific symposium entitled, "OCT & FFR, Current Applications, Future Potential." The symposium will take place on Thursday, Sept. 23 from 7 p.m. to 9:30 p.m. in the Renaissance Ballroom, located in the Renaissance Washington, D.C. Downtown Hotel.

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended April 3, 2010. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2024 to Jul 2024